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Abstract
STGC3 is a potential tumor suppressor that inhibits the growth of the nasopharyngeal carcinoma cell line CNE2; the
expression of this protein is reduced in nasopharyngeal carcinoma compared with normal nasopharyngeal tissue. In
this study, we investigated the tumor-suppressing activity of STGC3 in nude mice injected subcutaneously with
Tet/pTRE-STGC3/CNE2 cells. STGC3 expression was induced by the intraperitoneal injection of doxycycline (Dox).
The volume mean of Tet/pTRE-STGC3/CNE2+Dox xenografts was smaller than that of Tet/pTRE/CNE2+Dox
xenografts. In addition, Tet/pTRE-STGC3/CNE2+Dox xenografts showed an increase in the percentage of apoptotic
cells, a decrease in Bcl-2 protein expression and an increase in Bax protein expression. A proteomic approach was
used to assess the protein expression profile associated with STGC3-mediated apoptosis. Western blotting con-
firmed the differential up-regulation of prohibitin seen in proteomic analysis. These results indicate that
overexpression of STGC3 inhibits xenograft growth in nude mice by enhancing apoptotic cell death through altered
expression of apoptosis-related proteins such as Bcl-2, Bax and prohibitin. These data contribute to our understand-
ing of the function of STGC3 in human nasopharyngeal carcinoma and provide new clues for investigating other
STGC3-associated tumors.
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Introduction
Nasopharyngealcarcinoma(NPC)isasquamous-cell
carcinoma that occurs in the epithelial lining of the
nasopharynx (Wei and Sham, 2005). This neoplasm has an
unusual ethnic and geographic distribution, with a high
prevalence in southern China, southeastern Asia, northern
Africa and Alaska. The annual incidence is as high as 25
cases per 100,000 people in endemic regions, which is
about 25-fold higher than in the rest of the world (Yu and
Yuan, 2002; Xiong et al., 2004; Bei et al., 2010). This re-
markable geographic and racial distribution of NPC indi-
cates that the development of this cancer may be related to
geneticandenvironmentalfactors(McDermottetal.,2001;
Yu and Yuan, 2002).
Current evidence suggests that multi-step genetic al-
terations, including the activation of oncogenes and/or in-
activation of tumor suppressor genes, may underlie NPC
tumorigenesis (Chen et al., 1999). The tumor suppressor
genes p16/MTS1, DLC1, CDH4, IGFBP-6 and DAB2 show
homozygousdeletionsorreducedexpressioninNPCtissue
(Lo et al., 1995; Sun et al., 1995; Kuo et al., 2010; Tong et
al., 2010; Du et al., 2011; Low et al., 2011).
Over-expression of the MYC, RAS, EZH2, FGF8b onco-
geneshasalsobeendetectedinsomeNPCtumors(Porteret
al., 1994; Lu et al., 2011; Lui et al., 2011). Furthermore,
loss of heterozygosity (LOH) studies have shown that NPC
tumors contain deletions on chromosomal arms that in-
clude 3p, 9p and 11q (Huang et al., 1994; Hu et al., 1996;
Hui et al., 1996).
A common region of allelic loss in NPC involves
chromosome 3p21.31-3p21.2 (Zeng et al., 2006a). Using
cDNA cloning and RACE procedures, we cloned a novel
gene known as STGC3 (GenBank accession no.
AY078383) related to NPC from the common minimal de-
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Research Articleletion region in 3p21 (He et al., 2004). The full-length
cDNAofSTGC3contains1271bpwitha438bpopenread-
ing frame that encodes a protein with a molecular mass of
~16kDa.STGC3proteinexpressioninNPCsamplesissig-
nificantlylowerthanthatinnormalnasopharyngealepithe-
lium. STGC3 inhibits the growth of nasopharyngeal
carcinoma CNE2 cells in vitro (He et al., 2008), although
thetumorsuppressorfunctionofthisproteinisstillunclear.
In this work, we used a Tet-on regulated mouse model and
proteomic analysis to examine the potential tumor suppres-
sor roles of STGC3.
Materials and Methods
Cell culture
CNE2 is a poorly differentiated NPC cell line.
CNE2/Tet/pTRE and CNE2/Tet/ pTRE/STGC3 cells gen-
erated as described elsewhere (He et al., 2008) were cul-
tured in PRIM1640 medium (Invitrogen, USA)
supplemented with 10% fetal calf serum at 37 °C in a hu-
midified atmosphere of 95% air - 5% CO2.
Experiments with nude mice
Three-week-old male BALB/c nude mice were ac-
quired from the Animal Centre of the Academia Sinica in
Shanghai, China. All animal experiments were approved
by the National Animal Care and Use Committee of China
and done within one week after arrival of the mice.
Twenty-four nude mice were randomly allocated into
four groups (n = 6 mice/group) for treatment with different
cells: CNE2+Dox, CNE2/Tet/pTRE+Dox (Vector+Dox),
CNE2/Tet/pTRE/STGC3+Dox (STGC3+Dox) and
CNE2/Tet/pTRE/STGC3+PBS (STGC3+PBS). The cells
were trypsinized, suspended in phosphate-buffered saline
(PBS) and 0.2 mL containing 2x10
6 cells was inoculated
under the right armpit of each mouse. The mice were also
injected intraperitoneally with either doxycycline (Dox,
20 mg/kg; Roche, Switzerland) or an equal volume of PBS
every day for 28 days (Zeng et al., 2006b). Tumor growth
was monitored by measuring two perpendicular diameters
with vernier calipers every three days, and tumor volume
was calculated using the formula W
2xLx0.52, where L is
thelengthandWisthewidthofthetumor.Themeantumor
size was plotted for each group and the ratio of inhibition
(expressed in %) was calculated as (Mean of the vector
group–Meanofthetransfectedgroup)/(Meanofthevector
group) x100.
Histological examination
Subcutaneoustumorsderivedfromthecellsindicated
in the previous section were excised from nude mice under
ether anesthesia. The tumors were rinsed twice in normal
saline then fixed in 4% neutral buffered formalin and em-
bedded in paraffin. The sections were mounted on slides,
deparaffinized with xylene, rehydrated through graded al-
cohols, stained with hematoxylin and eosin (H&E) and
observed by light microscopy.
RNA extraction and RT-PCR
Total RNA was isolated from xenograft tissues using
Trizolreagent(Invitrogen)accordingtothemanufacturer’s
instructions. Single-stranded cDNA was generated from
2 g of total RNA using a first-strand cDNA synthesis kit
(Promega, USA) according to the manufacturer’s instruc-
tions.STGC3mRNAwasamplifiedwiththefollowingspe-
cificprimers:forward,5’-CGGGATCCATGGTTCTTG
TTT CTT AT-3’ and reverse, 5’-GCC CCA AGC TTT
AGA GTA ATA AAA GAT TC-3’. PCR was done for 30
cycles, each consisting of denaturation at 94 °C for 1 min,
annealing at 56 °C for 50 s, extension at 72 °C for 1 min.
-Actin (forward primer, 5’- GGA CCT GAC TGA CTA
CCT C-3’, reverse primer, 5’- CAT ACT CCT GCT TGC
TGA T-3’) was used as an endogenous control gene to con-
firm that equal amounts of sample mRNA were applied to
the gels; this gene was also used to normalize the results.
Protein extraction and western blotting
Xenografttissueswereextractedinlysisbuffer(0.5%
Nonidet P-40/5% sodium deoxycholate/150 mM NaCl/10
mM Tris/HCl, pH 7.5/1% BSA) and centrifuged at 4 °C for
15min.ThesampleswereseparatedbySDS-PAGEin10%
polyacrylamide gels and transferred to PVDF membranes
(Millipore,USA).Themembraneswereincubatedwith5%
fat-free milk at room temperature for 1 h, blotted with
anti-STGC3 (1:1000) (He et al., 2008), anti-prohibitin
(1:2000; Abcam, USA) and anti--actin (1:5000; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) antibodies at
room temperature for 2 h, washed, and then incubated with
peroxidase-conjugate secondary antibody (1:3000; Santa
Cruz Biotechnology). Immunoreactive bands were de-
tected by enhanced chemiluminescence (Amersham Bio-
sciences, Sweden).
Immunohistochemistry
Immunohistochemistry was done in formalin-fixed,
paraffin-embedded tissue sections using a standard
immunohistochemical technique. The sections were incu-
bated with anti-STGC3 (1:100), anti-Bcl-2 (1:200) and
anti-Bax (1:200) antibodies (Santa Cruz Biotechnology)
overnight at 4 °C and then incubated with a bio-
tin-conjugated secondary antibody (1:500; Santa Cruz Bio-
technology) for 60 min at room temperature. Finally, the
tissue sections were incubated with diaminobenzidine
(DAB, Santa Cruz Biotechnology) until a brown color de-
veloped, after which the sections were counterstained with
Harris’ modified hematoxylin. Sections incubated with
PBS instead of the corresponding primary antibody were
used as negative controls. The integral optical densities
(IOD) were calculated using PIPS-2020 image analysis
software.
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Cellsuspensionswerepreparedfromxenografttumor
tissue from each of the four groups of mice. After
centrifugation and dilution to 1x10
6 cells/mL, the cells
were fixed in 70% ethanol and stored in fixative at -20 °C
until analyzed for apoptosis. Fixed cells were washed with
PBS and incubated with propidium iodide (50 g/mL in
PBS) for 30 min at room temperature in the dark prior to
analysis by flow cytometry.
Two-dimensional (2D) electrophoresis
The tissue samples were suspended in lysis buffer
(7 M urea, 2 M thiourea, 2% NP-40, 1% Triton X-100,
100 mM DTT, 5 mM PMSF, 4% CHAPS, 0.5 mM EDTA,
40 mM Tris and 2% pharmalyte) at 4 °C for 1 h, and then
centrifuged (12,000 rpm, 30 min, 4 °C). The supernatants
were collected and the concentration of total proteins was
assayed with a 2D-electrophoresis quantification kit
(Amersham Biosciences). Isoelectric focusing was done
with an IPGphor system using IPG strips (pH 3-10 L,
24cm;AmershamBiosciences)followedbySDS-PAGEin
an Ettan DALT II system (Amersham Biosciences). After
SDS-PAGE, analytical 2D gels were used for 2D western
blottingandpreparative2Dgelswereusedforproteiniden-
tification by mass spectrometry following staining with
Coomassie blue G-250.
Image analysis
Coomassie blue-stained 2D gels were scanned with
MagicScan software on an Image scanner and analyzed
with a PD-Quest system (Bio-Rad Laboratories, USA) ac-
cordingtoprotocolsprovidedbythemanufacturer.Thecri-
terion for determining differential protein spot expression
was a two-fold increase or decrease in spot intensity be-
tween the groups being compared.
MALDI-TOF-MS and database analysis
Protein spots that showed changes in the intensity of
staining were excised from 2D gels and destained with
100 mM NH4HCO3 in 50% acetonitrile. The tryptic pep-
tides were extracted with 50% acetonitrile/2.5% trifluo-
roacetic acid, purified on ZipTip C18 columns (Millipore)
and mixed with a 4-hydroxy--cyanocinnamic-acid
(HCCA)solutionfollowedbyanalysiswithaVoyagerSys-
tem 4307 MALDI-TOF mass spectrometer (ABI). A tryp-
sin-fragment peak served as the internal standard for mass
calibration.Alistofthecorrectedmasseswasusedforpep-
tide mass fingerprinting and proteins were identified by da-
tabase searches for each peptide mass
(http://www.matrixscience.com).
Statistical analysis
All assays were done at least three times and the re-
sults were expressed as the mean  SD unless otherwise
stated. Statistical analyses were done using Student’s t-test
or one-way analysis of variance (ANOVA) followed by
Tukey’smultiplecomparisonstest.Valuesofp<0.05indi-
cated statistical significance.
Results
Overexpression of STGC3 inhibits tumor growth of
CNE2 cells increase the differentiation in vivo
We have previously described a CNE2 cell line with
inducible STGC3 expression (He et al., 2008). This cell
line,referredtoasTet/pTRE-STGC3/CNE2,wasoriginally
transfected with the pRevTet-on regulator plasmid and the
pRevTRE-STGC3 expression plasmid. Basal (uninduced)
STGC3expressioninthiscelllineisnormallyundetectable
but can be markedly enhanced (induced) by exposure to
doxycyclin (1 g/mL). We speculated that Tet/pTRE-
STGC3/CNE2 could also be induced in vivo. To test this
hypothesis, Tet/pTRE-STGC3/CNE2 cells were injected
subcutaneously into nude mice and STGC3 expression was
induced by daily intraperitoneal injections of doxycyclin
(20 mg/kg; Figure 1A). RT-PCR, western blotting and
immunohistochemical analysis showed that STGC3 was
highly expressed in Tet/pTRE-STGC3/CNE2+Dox xeno-
grafts (Figure 2).
To determine whether STGC3 inhibits tumor growth,
we measured the tumor masses and volumes. Tumors de-
rived from Tet/pTRE-STGC3/CNE2 cells exposed to Dox
(STGC3+Dox group) were smaller (1.74  0.66 g) than
those in the other three groups [CNE2+Dox: 2.86  0.83 g,
Tet/pTRE/CNE2+Dox (Vector+Dox): 2.76  0.73 g,
Tet/pTRE-STGC3/CNE2+PBS (STGC3+PBS): 2.72 
0.73 g]. The maximum suppression of tumor growth by
Tet/pTRE-STGC3/CNE2+Dox cells compared to
Tet/pTRE/CNE2+Dox cells was 37% (Figure 1A). Time-
volume curves for the xenografts showed that tumors in the
Tet/pTRE-STGC3/CNE2+Dox group had a slower growth
rate than those in the other three groups (p < 0.05;
Figure 1B).
Previous work with CNE2 cells in vitro showed that
STGC3 suppressed anchorage-independent cell growth in
softagar,indicatingatumor-suppressorroleforthisprotein
(He et al., 2008). Based on this observation, we used
xenograft tissue to assess whether STGC3 affected tumor
malignancy in vivo. Histological analysis of sections
stained with H&E showed that xenografts with high
STGC3 expression were more differentiated than those in
the other three groups. In cells overexpressing STGC3, the
nuclei were smaller and more regular in size and shape, the
nucleoli were less prominent and the cytoplasm was more
abundant (Figure 1C). These results indicate that
overexpression of STGC3 decreases the malignancy of
CNE2 cells in vivo.
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and affects the expression of Bcl-2 and Bax
associated with apoptosis
To determine the molecular mechanism by which the
overexpression of STGC3 causes tumor inhibition in vivo,
we used flow cytometry to examine apoptosis in cells from
xenograft tumors. Compared to Tet/pTRE/CNE2+DOX
xenografts, Tet/pTRE-STGC3/CNE2+Dox xenografts
showedasignificantincreaseinthepercentageofapoptotic
cells (11.4  1.2% vs. 1.5  0.6%; p < 0.01; Figure 3A). To
confirm these results, we examined expression of the apop-
tosis regulatory protein Bax and the anti-apoptotic protein
Bcl-2. In agreement with the flow cytometry results, Bax
protein expression was up-regulated and Bcl-2 protein ex-
pression was down-regulated in Tet/pTRE-
STGC3/CNE2+Dox xenografts (Figure 3B,C). The
Bcl-2/Bax ratio in the Tet/pTRE-STGC3/CNE2+Dox
groupwassignificantlylowerthanintheotherthreegroups
(Table 1 and Figure 3C). These findings suggest that
STGC3 increases the percentage of apoptotic cells by
down-regulatingBcl-2expressionandup-regulatingthatof
Bax.
Differential expression of proteins associated with
overexpression of STGC3
The nuclear location of STGC3 (Figure 2C) suggests
that this protein probably has an important role in regulat-
ing nuclear gene transcription. To test this hypothesis, we
undertook a comparative proteomic analysis of
Tet/pTRE/CNE2+Dox and Tet/pTRE-STGC3/CNE2+Dox
xenograft tissues. Figure 4A shows representative exam-
ples of the xenograft tissue proteins separated by 2D elec-
trophoresis. A total of 781  57 (n = 3 runs) and 749  46
(n = 3 runs) protein spots were detected in
Tet/pTRE/CNE2+Dox and Tet/pTRE-STGC3/CNE2+Dox
xenograft tissues, respectively. Proteins that consistently
showed a greater than two-fold change in expression were
included in the analysis (Figure 4B).
The differentially expressed protein spots were ex-
cised from Coomassie blue-stained gels and subjected to
in-gel digestion with trypsin. An aliquot of the supernatant
containing tryptic peptides was analyzed by MALDI-
TOF-MS (Figure 4C). Only proteins with a significant
score in the Mascot database were identified as being dif-
ferentially expressed. Figure 4A shows that 11 differen-
tially expressed proteins were identified in
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Figure 1 - Over-expression of STGC3 inhibits tumor growth and decreases malignancy in nude mice. (A) Comparison of subcutaneously injected
xenograftsofnudemice.(B)Time-volumecurvesforthexenografts.*p<0.05comparedwiththeVector+Doxgroup.(C)STGC3decreasesmalignancy
in xenograft tissue. Sections were stained with H&E.Tet/pTRE/CNE2+Dox and Tet/pTRE-STGC3/CNE2+Dox
xenograft tissues. Detailed information for eight of the 11
proteinsidentifiedisprovidedinTable2;threeproteinsnot
included in this table were classified as unknown by the
Swiss-Prot website.
Searches of the Swiss-Prot and PubMed databases
were used to determine the functions of the identified pro-
teinsrelatedtoSTGC3.Proteinsinvolvedinapoptosiswere
either up-regulated, e.g., prohibitin, or down-regulated,
e.g., heat shock 70 protein 8 isoform 2 variant (Powers et
al., 2008; Zhu et al., 2010), as were those involved in cell
proliferation, e.g., petidyl-prolyl cis-trans isomerase A
(up-regulated) and splicing factor arginine/serine-rich 1
(down-regulated) (Colgan et al., 2000; Karni et al., 2007),
the cytoskeleton, e.g., cofilin-1 (up-regulated) (Chae et al.,
2009), and signal pathways, e.g., serine/threonine-protein
kinase WNK1 (down-regulated) and guanine nucleotide-
binding protein subunit beta 2-like 1 (up-regulated), when
STGC3 was highly expressed in xenograft tissues (Moniz
and Jordan, 2010; Zhang et al., 2010).
STGC3 increases the expression of prohibitin, a
protein associated with apoptosis
To confirm the differential expression of the proteins
identified by proteomic analysis, western blotting was used
to compare the expression of prohibitin in Tet/pTRE-
STGC3/CNE2+Dox xenograft tissue with that in
Tet/pTRE/CNE2+Dox xenograft tissue. Figure 4D shows
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Figure 2 - Dox induces a high level of STGC3 expression in Tet/pTRE-STGC3/CNE2 cells. (A) RT-PCR of STGC3 mRNA expression in xenograft tis-
sue. (B) Detection of STGC3 protein by western blotting with an anti-STGC3 antibody. These results agreed with the RT-PCR data.
(C) Immunohistochemical staining for STGC3 in xenograft tissue.
Table1-EffectofSTGC3onBcl-2andBaxexpressionintumorsections.
Groups Optical density
Bcl-2 Bax Bcl-2/Bax
CNE2+Dox 48.6  7.6 16.2  3.6 3.00
Vector +Dox 47.4  6.1 14.2  1.5 3.34
STGC3+PBS 49.4  6.4 15.6  2.4 3.17
STGC3+Dox 19.2  3.7 51.4  11.5 0.37*
The values are the mean SD of six sections per group. *p < 0.05 com-
pared with the Vector+Dox group.representative western blotting of prohibitin expression in
Tet/pTRE/CNE2+Dox and Tet/pTRE-STGC3/CNE2+Dox
xenograft tissues. Prohibitin expression in Tet/pTRE-
STGC3/CNE2+Dox tissue was 4.5-fold greater than in
Tet/pTRE/CNE2+Dox tissue. These results were identical
to those obtained with 2D electrophoresis.
Discussion
In this study, mice received subcutaneous injections
of Tet/pTRE-STGC3/CNE2 cells and STGC3 expression
was induced by the intraperitoneal injection of Dox. The
Tet-on gene system was developed by Gossen and Bujard
(1992), who found that gene expression can be easily mod-
ulated via the administration of Dox, which is minimally
toxic and targets specific genes. As shown here, the intra-
peritoneal injection of Dox in mice is highly effective in
stimulating overexpression of the STGC3 gene.
In vitro, STGC3 inhibits the growth of CNE2 cells
and suppresses the anchorage-independent growth of these
cells in soft agar, implying a tumor-suppressor role for this
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Figure3-STGC3inhibitsthetumorgrowthofCNE2cellsinnudemicebyincreasingthepercentageofapoptoticcellsandmodulatingtheexpressionof
theapoptosis-relatedproteinsBcl-2andBax.(A)ThepercentageofapoptoticcellswasincreasedinTet/pTRE-STGC3/CNE2+Doxxenografts.*p<0.01
comparedwiththeVector+Doxgroup.(B)ImmunohistochemicalstainingforBcl-2andBaxinxenografttissue.(C)(a)Bcl-2andBaxproteinexpression
in xenograft tissue assessed by western blotting. (b) Protein levels normalized to -actin. *p < 0.05 compared with the Vector+Dox group.24 STGC3 inhibits xenograft tumor growth
Figure 4 - Comparative proteomic analysis of Tet/pTRE/CNE2+Dox and Tet/pTRE-STGC3/CNE2+Dox xenograft tissues by 2D electrophoresis, mass
spectrometry and western blotting. (A) 2D electrophoretic maps of Tet/pTRE/CNE2+Dox and Tet/pTRE-STGC3/CNE2+Dox xenograft tissue proteins.
(B) A close-up of the 2D gel showing the marked overexpression of protein spot 4 in Tet/pTRE-STGC3/CNE2+Dox tissue compared with
Tet/pTRE/CNE2+Doxtissue.(C)MALDI–TOFmassspectrometricanalysisofdifferentialproteinspot4.(D)(a)Westernblottingofprohibitinexpres-
sion in Tet/pTRE/CNE2+Dox and Tet/pTRE-STGC3/CNE2+Dox xenograft tissues. (b) Protein levels normalized to  -actin. *p < 0.05 compared with
the Vector group.
Table 2 - Up-regulated and down-regulated spots in the Tet/pTRE-STGC3/CNE2+Dox group.
Spot Accession
number
Expressed in
STGC3+Dox
Peptide
matches
pI MW Sequence
coverage (%)
Protein identity
1 P62938  9/26 7.82 13,098 58 Peptidyl-prolyl cis-trans isomerase A
3 P23528  5/17 8.26 18,588 53 Cofilin-1
4 A46117  7/28 5.57 29,843 36 Prohibitin
5 P63243  19/38 7.56 35,380 51 Guanine nucleotide-binding protein subunit 2-like 1
6 A46160  3/9 6.51 3,805 83 Serine/threonine-protein kinase WNK1
7 Q07955  15/77 7.72 22,560 70 Splicing factor arginine/serine-rich 1
8 Q53HF2  14/57 5.62 53,580 65 Heat shock 70 protein 8 isoform 2 variant
11 P13646  10/22 8.27 22,324 67 Triosephosphate isomerase
Notethatofthe11proteinswithalteredexpression,three(proteins2,9and10;notshownintheTable)wereidentifiedas‘unknown’indatabasesearches.
‘Peptidematches’indicatesthenumberofmatchesfoundindatabasesearchescomparedtothetotalnumberofpeptidesgeneratedbytrypticdigestion.protein in the development of NPC (He et al., 2008). The
results described here indicate that the overexpression of
STGC3 inhibits xenograft growth in nude mice, thus con-
firming the tumor suppressor role of STGC3 in the devel-
opmentofNPC.Theincreaseinthepercentageofapoptotic
cells when STGC3 was overexpressed indicates that this
protein inhibits tumor growth by enhancing apoptosis. This
finding was related to the ratio of pro-apoptotic and anti-
apoptoticproteinsinthecell.Bcl-2isanimportantsuppres-
sor of apoptosis while Bax is a key apoptosis inducer. Cells
with a low Bcl-2:Bax ratio are more likely to undergo
apoptosis than those with a high Bcl-2:Bax ratio (Xie et al.,
1999; Qin et al., 2008). As shown here, Bcl-2 protein ex-
pression was down-regulated and Bax protein expression
was up-regulated in Tet/pTRE-STGC3/CNE2+Dox xeno-
grafts. These data suggest that STGC3 inhibited the growth
of CNE2 cells by altering the ratio of pro-apoptotic and
anti-apoptotic proteins.
Proteomic analysis is a powerful tool for the global
evaluation of protein expression and has been widely ap-
plied in the study of diseases, especially in cancer research.
Differential protein expression profiling by 2D electropho-
resis is a crucial part of proteomics that can provide accu-
rate, reproducible results on protein expression in two or
more biological samples. In the present study, we detected
11proteinsthatweredifferentiallyexpressedinresponseto
the overexpression of STGC3. Among these proteins, we
focusedonprohibitin,whichisinvolvedintheregulationof
cell apoptosis. Zhu et al. (2006) reported that prohibitin is
an intracellular mediator in the signaling pathway of trans-
forming growth factor , a potent apoptosis inducer. The
induction of prohibitin is also an indicator of mitochondrial
destabilization during apoptosis-related events (Thompson
et al., 2001). Many apoptotic signals converge at the level
of the mitochondria and release mitochondrial proteins that
promote apoptosis. Prohibitin stabilizes mitochondrial
membrane proteins such as Bcl-2 and Bax (Manjeshwar et
al., 2003). The tumor suppressor role of STGC3 may be as-
sociated with the up-regulation of prohibitin and result in
increased apoptosis by affecting the mitochondrial-
associated proteins Bcl-2 and Bax.
In conclusion, STGC3 inhibits xenograft growth by
increasing the percentage of apoptotic cells through alter-
ations in the expression of various genes involved in apop-
tosis, including the down-regulation of Bcl-2 and up-
regulation of Bax. STGC3 also affects the expression of
genes related to proliferation, the cytoskeleton and cell sig-
naling. The putative tumor suppressor prohibitin was iden-
tifiedasanimportantcandidateproteinaffectedbySTGC3.
Together, these findings indicate that STGC3 probably has
an important role in suppressing NPC tumorgenesis. They
also provide a foundation for future investigations of the
molecular mechanisms involved in STGC3-mediated tu-
mor suppression.
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